Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?

 

Medic, Hospital, Laboratory, Medical, Health, Doctor

AZN – Although the FDA has issued Emergency Use Authorizations (EUAs) only for the COVID-19 vaccines developed by Moderna and Pfizer-BioNTech, several other vaccine candidates are still in development. The vaccines developed by Astrazeneca (AZN) and Novavax (NVAX) are still awaiting EUAs, but they reportedly show much promise in their late-stage clinical trials. So, let’s find out which of these two stocks is a better buy now.

Astrazeneca PLC (AZN - Get Rating) and Novavax, Inc. (NVAX - Get Rating) are two of the leading COVID-19 vaccine developers that have been in the news.  While neither of  these companies will have a first-mover advantage if and when their vaccines are eventually brought to market (vaccines developed by Moderna and Pfizer-BioNTech are already being deployed with an Emergency Use Authorization (EUA) granted by the FDA), their late-stage clinical trial results of AZN and NVAX are said to show a lot of promise.

Both AZN and NVAX are expected to generate massive returns in the coming months when their vaccines hit the market and help to beat back the spread of  COVID-19. However, nothing is for certain and there are several factors that could determine the prospects of these two stocks.

While AZN has returned 71.8% over the past five years, NVAX has gained 229.2%. In terms of their year-to-date performance, NVAX is a clear winner with 167.5% returns versus AZN’s 0.2%. But which of these two stocks is a better pick now? Let’s find out.

Latest Movements

Following the European Medicines Agency (EMA) approval, AZN began the delivery of millions of its coronavirus vaccines on February 5 as part of an  initial 17 million doses that are due to be delivered over the next few weeks, with more planned in March. The company, along with IDT Biologika, is  also exploring options to accelerate output of its  COVID-19 vaccines in the second quarter of 2021  to help support Europe’s immediate vaccination needs.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
William K. 2 weeks ago Member's comment

Thanks for the quite deep analysis in this area. Now considering the gross profit margin ratio of about 80/8 there is a question in my mind as to the validity of the comparison. Are they comparing Apples to Oatmeal?

Then comparing sizes based on published revenue figures, there is a large size difference.

So the question becomes one of buying shares of a large company that is doing well or a much smaller company that is doing "OK", and it seems that there is a recommendation here in fairly plain sight.

Dragan 2 weeks ago Member's comment

Think this is crap, don't agree at all.

Alpha Stockman 2 weeks ago Member's comment

The article isn’t wrong based off currently commercialized products (we have none)... and there is a chance that things could still end badly for $NVAX. But the odds are so much in our favor now that, at least for the next few weeks, investing in NVAX is like printing free money.

Andrew Armstrong 2 weeks ago Member's comment

My vote goes to #Novavax.

Karen Klein 2 weeks ago Member's comment

$AZN looks like the best option since it's easy to transport and so cheap to produce. But it sounds like it's not particularly effective against the new strains.

Adam Reynolds 2 weeks ago Member's comment

This article states the #Novavax $NVAX is overvalued. Market cap? Revenue potential?